Immunocore is a pioneering, clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.
$47.56 -1.44 (-2.94%)
As of 02/26/2021 15:55:35 EST IEX book CBOE book
2021 © Stock Market MBA, Inc.